EW · News · 20260805N
Guidance / Outlook
Edwards Lifesciences Corp · 2026-08-05 · Importance 28 · Surprise 42
Edwards Lifesciences provided optimistic guidance for the third quarter and full year 2026. The reporting did not specify the associated revenue, margin, or earnings targets. The company’s latest reported revenue was approximately $1.74 billion, but no separate financial impact from the updated outlook was disclosed.
Key facts
- EW DCF analysis: Intrinsic Value $53 vs Price $90 (dated August 05, 2026). source